Donna, here is part of the patent it is so large this is only a part of it but you can Google it if you want to read it all. Patents Find prior artDiscuss this applicationView PDFDownload PDF Publication number US20120251502 A1 Publication type Application Application number US 13/125,890 PCT number PCT/US2009/062079 Publication date Oct 4, 2012 Filing date Oct 26, 2009 Priority date Oct 24, 2008 Also published as CA2741523A1, 4 More » Inventors Jonathan S. Towner, 4 More » Original Assignee The Government of the US as Represented by the Secretary of the Dept. of health Export Citation BiBTeX, EndNote, RefMan Patent Citations (2), Non-Patent Citations (8), Classifications (39), Legal Events (1) External Links: USPTO, USPTO Assignment, Espacenet Human Ebola Virus Species and Compositions and Methods Thereof US 20120251502 A1 ABSTRACT Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection. IMAGES(27) Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Patent Drawing Next page CLAIMS(30) 1. An isolated hEbola virus comprising a nucleic acid molecule comprising a nucleotide sequence of: a) a nucleotide sequence set forth in SEQ ID NOS: 1 or 10; b) a nucleotide sequence hybridizing under stringent conditions to SEQ ID NOS: 1 or 10; or c) a nucleotide sequence of at least 70%-99% identity to the SEQ ID NOS: 1 or 10, with the proviso that said nucleotide sequence is not SEQ ID NO: 20. 2. An isolated hEbola virus having Centers for Disease Control Deposit Accession No. 200706291. 3. The hEbola virus of claim 1 which is killed. 4. The hEbola virus of claim 1 which is an attenuated hEbola virus. 5. The virus of claim 4 wherein at least one property of the attenuated hEbola virus is reduced from among infectivity, replication ability, protein synthesis ability, assembling ability or cytopathic effect. 6. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS: 1 or 10 or a complement thereof, or a fragment thereof wherein said fragment comprises a nucleotide sequence of between 4 and 4900 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof; with the proviso that said nucleotide sequence is not comprised by the nucleotide sequence set forth in SEQ ID NO: 20; or between 5500 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof. 7. The isolated nucleic acid molecule of claim 6 comprising a nucleotide sequence of between 4 and 4900 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof; with the proviso that said nucleotide sequence is not comprised by the nucleotide sequence set forth in SEQ ID NO: 20; or between 5500 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof. 8. The isolated nucleic acid molecule of claim 7 comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2-9, 59, or SEQ ID NO: 11-19 or a complement thereof. 9. An isolated RNA or DNA nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS: 1 or 10 or a complement thereof. 10. An isolated polypeptide encoded by the nucleic acid molecule of claim 7. 11. The polypeptide of claim 10 comprising the amino acid of: a) an amino acid sequence set forth in any of SEQ ID NOS: 2-19, or 59; or b) an amino acid sequence that has 70%-99% homology to the amino acid sequence of (a). 12. The polypeptide of claim 10 wherein the amino acid sequence has 5 to 250 contiguous amino acid residues of the amino acid sequence of SEQ ID NOS: 5 or 18 (VP24); 5 to 280 contiguous residues of the amino acid sequence of SEQ ID NOS: 6 or 17 (VP30); 5 to 320 contiguous residues of the amino acid sequence of SEQ ID NOS: 8 or 13 (VP40); 5 to 340 contiguous residues of the amino acid sequence of SEQ ID NOS: 7 or 12 (VP35); 5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS: 4 or 15 (SGP); 5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS: 59 or 16 (SSGP); 5 to 670 contiguous residues of the amino acid sequence of SEQ ID NOS: 9 or 14 (GP); 5 to 730 contiguous residues of the amino acid sequence of SEQ ID NOS: 3 or 11 (NP); or 5 to 2200 contiguous residues of the amino acid sequence of SEQ ID NOS: 2 or 19 (L). 13. (canceled) 14. (canceled) 15. (canceled) 16. (canceled) 17. (canceled) 18. (canceled) 19. (canceled) 20. The hEbola virus of claims 3 or 4, or a protein extract therefrom, and a pharmaceutically acceptable carrier. 21. (canceled) 22. The nucleic acid molecule of claims 6 or 9, and a pharmaceutically acceptable carrier. 23. (canceled) 24. (canceled) 25. (canceled) 26. (canceled) 27. (canceled) 28. (canceled) 29. (canceled) 30. (canceled) DESCRIPTION RELATED APPLICATIONS This application claims priority benefit of U.S. Provisional Application 61/108,175 filed 24 Oct. 2008; the contents of which are hereby incorporated by reference. DEPOSIT STATEMENT The invention provides the isolated human Ebola (hEbola) viruses denoted as Bundibugyo (EboBun) deposited with the Centers for Disease Control and Prevention (“CDC”; Atlanta, Ga., United States of America) on Nov. 26, 2007 and accorded an accession number 200706291. This deposit was not made to an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and is a non-Budapest treaty deposit. The deposited organism is not acceptable by American Type Culture Collection (ATCC), Manassas, Va., an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Samples of the stated Deposit Accession No. 200706291 will be made available to approved facilities for thirty years from the date of deposit, and for the lifetime of the patent issuing from, or claiming priority to this application. FIELD OF THE INVENTION The invention is related to compositions and methods directed to a novel species of human Ebola (hEbola) virus. BACKGROUND OF THE INVENTION The family Filoviridae consists of two genera, Marburgvirus and Ebolavirus, which have likely evolved from a common ancestor1. The genus Ebolavirus includes four species: Zaire, Sudan, Reston and Côte dIvoire (Ivory Coast) ebolaviruses, which have, with the exception of Reston and Côte dIvoire ebolaviruses, been associated with large hemorrhagic fever (HF) outbreaks in Africa with high case fatality (53-90%)2. Viruses of each species have genomes that are at least 30-40% divergent from one another, a level of diversity that presumably reflects differences in the ecological niche they occupy and in their evolutionary history. Identification of the natural reservoir of ebolaviruses remains somewhat elusive, although recent PCR and antibody data suggest that three species of arboreal fruit bats may be carriers of Zaire ebolavirus3. No data has yet been published to suggest reservoirs for the Sudan, Reston and Côte dIvoire ebolavirus species. However, a cave-dwelling fruit bat has been recently implicated as a natural host for marburgvirus4, 5, supporting the hypothesis that different bat species may be the reservoir hosts for the various filoviruses. Filovirus outbreaks are sporadic, sometimes interspersed by years or even decades of no apparent disease activity. The last new species of ebolavirus was discovered 14 years ago (1994), in Cote dIvoire (Ivory Coast), and involved a single non-fatal case, a veterinarian who performed an autopsy on an infected chimpanzee found in the Tai Forest6. No further disease reports have been associated with Côte dIvoire ebolavirus, in contrast to Zaire and Sudan ebolaviruses which have each caused multiple large outbreaks over the same time period. In late November 2007, HF cases were reported in the townships of Bundibugyo and Kikyo in Bundibugyo District, Western Uganda. The outbreak continued through January 2008, and resulted in approximately 149 cases and 37 deaths2. Laboratory investigation of the initial 29 suspect-case blood specimens by classic methods (antigen capture, IgM and IgG ELISA) and a recently developed random-primed pyrosequencing approach identified this to be an Ebola HF outbreak associated with a new discovered ebolavirus species. These specimens were negative when initially tested with highly sensitive real-time RT-PCR assays specific for all known Zaire and Sudan ebolaviruses and Marburg viruses. This new species is referred to herein as “the Bundibugyo species”, abbreviated “EboBun”. Accordingly, compositions and methods directed to the new Ebola virus species are described herein and the most closely related Ebola Ivory Coast species, which compositions and methods are useful for diagnosis and prevention of human Ebola virus infection; including related vaccine development, and prevention of hemorrhagic fever in a human population.
Posted on: Mon, 04 Aug 2014 15:25:14 +0000
Trending Topics
Recently Viewed Topics
© 2015